13 Mar 2017 07:00
Press release
Publication of Form 20-F
London: Monday, March 13, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today published the Form 20-F for the financial year ended December 31, 2016. This is available for viewing at http://www.rns-pdf.londonstockexchange.com/rns/2395Z_-2017-3-13.pdf and also on the Company's website at www.chi-med.com.
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited ("CK Hutchison") (SEHK: 0001). For more information, please visit: www.chi-med.com.
Contacts
Investor Enquiries | |||
Christian Hogg, CEO | +852 2121 8200 | ||
U.K. & International Media Enquiries | |||
Anthony Carlisle,Citigate Dewe Rogerson | +44 7973 611 888 (Mobile) | anthony.carlisle@cdrconsultancy.co.uk | |
U.S. Based Media Enquiries | |||
Brad Miles, BMC Communications | +1 (917) 570 7340 (Mobile) | bmiles@bmccommunications.com | |
Susan Duffy, BMC Communications | +1 (917) 499 8887 (Mobile) | sduffy@bmccommunications.com | |
Investor Relations | |||
Matt Beck, The Trout Group | +1 (917) 415 1750 (Mobile) | mbeck@troutgroup.com | |
David Dible, Citigate Dewe Rogerson | +44 7967 566 919 (Mobile) | david.dible@citigatedr.co.uk | |
Panmure Gordon (UK) Limited | |||
Richard Gray / Andrew Potts | +44 (20) 7886 2500 | ||
Hutchmed (HCM)